Laidlaw & Company is an independent investment banking and securities brokerage firm. Established over 170 years ago, it has created a network of service providers in both the US and Europe.
Laidlaw markets itself as a firm for all, with a primary focus on the healthcare and mining industries. The company website stresses its workforce’s strong work ethic, and ability to “think outside the box”. The retail sales force is praised for its expertise in helping emerging companies secure the funding to become established and even expand.
Perhaps the single largest issue facing Laidlaw is the temporary restraining order issued against it in December 2015, as a result of litigation involving Relmada Therapeutics. Relmada Therapeutics researches diseases of the central nervous system, with the goal of developing innovative treatments for chronic pain. Laidlaw had previously served as Relmada’s investment banker but was accused of releasing false information in an effort to take over Relmada’s operation and invesstments. This legal action not only named Laidlaw & Company but specifically included Eitner and Ahern in the suit.
Relmada’s lawsuit was recently refiled in 2016 and so the cloud of mistrust continues to follow Laidlaw & Company.
Here are the sources I used: